title: Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.
abstract: For the 127 Spanish patients enrolled in the Combine Study, a resistance substudy was performed with 100 (79%) plasma samples obtained at baseline and with 18 samples obtained from 19 patients at the time they experienced treatment failure. At baseline, primary mutations to nonnucleoside reverse-transcriptase inhibitors and protease inhibitors were not detected, whereas mutations to nucleoside reverse-transcriptase inhibitors were observed in 10% of patients. At failure, mutations were detected in 7 of 16 patients. An agreement in the results of virtual and real phenotypes was observed in the 93 samples in which both tests were performed.
authors.affiliation: Infectious Disease Service, Hospital Universitario de Bellvitge, Barcelona, Spain.
authors.forename: Elena
authors.initials: E
authors.lastname: Ferrer
authors.forename: Daniel
authors.initials: D
authors.lastname: Podzamczer
authors.forename: Mireia
authors.initials: M
authors.lastname: Arnedo
authors.forename: Emilio
authors.initials: E
authors.lastname: Fumero
authors.forename: Paula
authors.initials: P
authors.lastname: McKenna
authors.forename: Alex
authors.initials: A
authors.lastname: Rinehart
authors.forename: José L
authors.initials: JL
authors.lastname: Pérez
authors.forename: María J
authors.initials: MJ
authors.lastname: Barberá
authors.forename: Tomás
authors.initials: T
authors.lastname: Pumarola
authors.forename: José M
authors.initials: JM
authors.lastname: Gatell
authors.forename: Francisco
authors.initials: F
authors.lastname: Gudiol
mesh_terms: D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D001118:Argentina; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008875:Middle Aged; D009154:Mutation; D019888:Nelfinavir / Q000627:therapeutic use*; D019829:Nevirapine / Q000627:therapeutic use*; D010641:Phenotype; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D013030:Spain; D017211:Treatment Failure; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D019829:Nevirapine; D019888:Nelfinavir